CLINICAL EFFICACY OF UMIFENOVIR IN ACUTE RESPIRATORY VIRAL INFECTIONS

Objective. To evaluate the clinical efficacy of umifenovir in acute respiratory viral infections (ARVI) in adult patients. Subjects and methods. The investigation covered 47 patients aged 18 to 60 years with ARVI, of them there were 26 (55.3%) men and 21 (44.7%) women. 53.2% of the patients were aged 18 to 30 years. According to the timing of their search for medical care and their treatment, the patients were divided into 2 groups: 1) 23 patients who started receiving treatment during the first 48 hours after onset of symptoms; 2) 24 patients sought medical advice at 2-3 days of the disease. All the patients received 2 umifenovir capsules 4 times daily for 5 days. To verify the diagnosis, the investigators applied a rapid influenza diagnostic technique by an immunochromatographic test using the Influenza A + B test system («Vegal Farmaceutica S.L.», Spain), a PCR assay for detecting the viruses of influenza and ARVI (nasopharyngeal swabs), as well as comprehensive examination including clinical blood analysis, general urinalysis, chest radiography, and electrocardiography (if necessary). Phagocytic activity of monocytes and granulocytes, IFN-like activity of serum and supernatant fluid of cultured blood cells incubated in the medium with addition of phytohemagglutinin (PHA) or Newcastle disease virus, or without them (interferon status) were studied over time. Results. A clinical effect is noted in the treatment of catarrhal respiratory syndrome, in the reduction of the febrile period, and more rapid recovery in Group 1. Conclusion. Early treatment can considerably shorten the duration of the disease and reduce its major symptoms and the risk of complications.

acute respiratory viral infections, influenza, umifenovir, interferons